Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Stem cell therapy to treat heart ischaemia : implications for diabetes cardiovascular complications. / Ali Qayyum, Abbas; Mathiasen, Anders Bruun; Kastrup, Jens.
In: Current Diabetes Reports, Vol. 14, 554, 12.2014, p. 1-8.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Stem cell therapy to treat heart ischaemia
T2 - implications for diabetes cardiovascular complications
AU - Ali Qayyum, Abbas
AU - Mathiasen, Anders Bruun
AU - Kastrup, Jens
PY - 2014/12
Y1 - 2014/12
N2 - Diabetes mellitus is a well-known risk factor for coronary artery disease (CAD), which can lead to acute myocardial infarction, chronic myocardial ischaemia and heart failure. Despite the advantages in medical treatment, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), morbidity and mortality is still high in patients with CAD. Along with PCI and CABG or in patients without options for revascularization, stem cell regenerative therapy in controlled trials is a possibility. Stem cells are believed to exert their actions by angiogenesis and regeneration of cardiomyocytes. Recently published clinical trials and meta-analysis of stem cell studies have shown encouraging results with increased left ventricle ejection fraction and reduced symptoms in patients with CAD and heart failure. There is some evidence of mesenchymal stem cell being more effective compared to other cell types and cell therapy may be more effective in patients with known diabetes mellitus. However, further investigations are warranted.
AB - Diabetes mellitus is a well-known risk factor for coronary artery disease (CAD), which can lead to acute myocardial infarction, chronic myocardial ischaemia and heart failure. Despite the advantages in medical treatment, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), morbidity and mortality is still high in patients with CAD. Along with PCI and CABG or in patients without options for revascularization, stem cell regenerative therapy in controlled trials is a possibility. Stem cells are believed to exert their actions by angiogenesis and regeneration of cardiomyocytes. Recently published clinical trials and meta-analysis of stem cell studies have shown encouraging results with increased left ventricle ejection fraction and reduced symptoms in patients with CAD and heart failure. There is some evidence of mesenchymal stem cell being more effective compared to other cell types and cell therapy may be more effective in patients with known diabetes mellitus. However, further investigations are warranted.
U2 - 10.1007/s11892-014-0554-5
DO - 10.1007/s11892-014-0554-5
M3 - Journal article
C2 - 25344789
VL - 14
SP - 1
EP - 8
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
M1 - 554
ER -
ID: 135544010